Nureca
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Nureca promoter-group director Smita Goyal bought 9,974 company shares for about ₹32.5 lakh in four on-market trades on the NSE and BSE between 26 and 28 August. Her holding rose from 45,320 shares, or 0.47%, to 55,294 shares, or 0.58%. Goyal had bought 45,313 shares for ₹1.41 crore in July, taking her holding to 0.47%. Nureca sells home healthcare and wellness products through an overwhelmingly online channel, which accounted for 87.6% of sales in the June quarter. The company reported FY26 revenue of ₹147.2 crore and has been expanding domestic manufacturing at Mohali.
Powered by Tijori
Nureca promoter-group director Smita Goyal bought 9,974 company shares for about ₹32.5 lakh in four on-market trades on the NSE and BSE between 26 and 28 August. Her holding rose from 45,320 shares, or 0.47%, to 55,294 shares, or 0.58%. Goyal had bought 45,313 shares for ₹1.41 crore in July, taking her holding to 0.47%. Nureca sells home healthcare and wellness products through an overwhelmingly online channel, which accounted for 87.6% of sales in the June quarter. The company reported FY26 revenue of ₹147.2 crore and has been expanding domestic manufacturing at Mohali.
Powered by Tijori
Nureca promoter-group member Smita Goyal bought 45,313 shares worth ₹1.41 crore in seven open-market transactions between 24 and 31 July, taking her holding to 45,320 shares, or 0.47%. The exchange system did not reflect the transactions, prompting a manual disclosure on 11 August. A July family-settlement transfer left Saurabh Goyal with 68.09% of Nureca. The company recorded revenue of ₹147.2 crore in FY26 and ₹40.3 crore in the June 2026 quarter.
Powered by Tijori
Nureca promoter-group member Smita Goyal bought 45,313 shares worth ₹1.41 crore in seven open-market transactions between 24 and 31 July, taking her holding to 45,320 shares, or 0.47%. The exchange system did not reflect the transactions, prompting a manual disclosure on 11 August. A July family-settlement transfer left Saurabh Goyal with 68.09% of Nureca. The company recorded revenue of ₹147.2 crore in FY26 and ₹40.3 crore in the June 2026 quarter.
Powered by Tijori
Nureca Ltd. disclosed on Saturday that certain promoter group members have entered into a family settlement agreement dated June 17, 2026. Under the agreement, Aryan Goyal and Payal Goyal will transfer all their shares in the company to Saurabh Goyal, the sole promoter and chairman. The transfer represents approximately 33.7% of the company's voting rights, increasing Saurabh Goyal's stake from 34.35% to 68.09%. Additionally, Aryan Goyal will step down as chief executive officer and resign as a director of Nureca, conditional on the settlement's completion. The company stated it is not a party to the agreement and has not independently verified its contents. The settlement is intended for family succession planning and reallocation of ownership interests among the promoter family members.
Powered by Tijori
Nureca Ltd. disclosed on Saturday that certain promoter group members have entered into a family settlement agreement dated June 17, 2026. Under the agreement, Aryan Goyal and Payal Goyal will transfer all their shares in the company to Saurabh Goyal, the sole promoter and chairman. The transfer represents approximately 33.7% of the company's voting rights, increasing Saurabh Goyal's stake from 34.35% to 68.09%. Additionally, Aryan Goyal will step down as chief executive officer and resign as a director of Nureca, conditional on the settlement's completion. The company stated it is not a party to the agreement and has not independently verified its contents. The settlement is intended for family succession planning and reallocation of ownership interests among the promoter family members.
Powered by Tijori
** Healthcare and wellness products provider Nureca NURE.NS rises as much as 5% to a near three-month high of 327.40 rupees; last up 2.8%
** Co's Q3 profit after tax jumps to 37 million rupees, compared with 28 million rupees loss reported a year ago
** Q3 revenue rises 50% YOY to 396 million rupees
** NURE rose 8.8% in 2025
(Reporting by Brijesh Patel in Bengaluru)
(([email protected]; Ph no. +91 9590227221;))
** Healthcare and wellness products provider Nureca NURE.NS rises as much as 5% to a near three-month high of 327.40 rupees; last up 2.8%
** Co's Q3 profit after tax jumps to 37 million rupees, compared with 28 million rupees loss reported a year ago
** Q3 revenue rises 50% YOY to 396 million rupees
** NURE rose 8.8% in 2025
(Reporting by Brijesh Patel in Bengaluru)
(([email protected]; Ph no. +91 9590227221;))
** Healthcare and wellness products provider Nureca NURE.NS falls 9.35% to 258.05 rupees
** Co's Q1 profit after tax halves to 8.1 million rupees in Q1 FY26 from 16.6 million rupees a year ago
** 70% y/y jump in revenue overshadowed by higher costs
** YTD, stock down ~9%
(Reporting by Ananta Agarwal in Bengaluru)
** Healthcare and wellness products provider Nureca NURE.NS falls 9.35% to 258.05 rupees
** Co's Q1 profit after tax halves to 8.1 million rupees in Q1 FY26 from 16.6 million rupees a year ago
** 70% y/y jump in revenue overshadowed by higher costs
** YTD, stock down ~9%
(Reporting by Ananta Agarwal in Bengaluru)
May 7 (Reuters) - Nureca Ltd NURE.NS:
IN-PRINCIPALLY APPROVES MERGER OF NURECA TECHNOLOGIES WITH CO
Source text: ID:nNSE3dg7jF
Further company coverage: NURE.NS
(([email protected];;))
May 7 (Reuters) - Nureca Ltd NURE.NS:
IN-PRINCIPALLY APPROVES MERGER OF NURECA TECHNOLOGIES WITH CO
Source text: ID:nNSE3dg7jF
Further company coverage: NURE.NS
(([email protected];;))
** Shares of Nureca NURE.NS gain as much as 5% to 225.1 rupees, last up 4.3%
** Healthcare and wellness product maker's unit completed registration with the United States Food and Drug Administration (USFDA)
** Medical devices from the unit's plant in Punjab state including beds and stethoscope now listed with USFDA for manufacturing and exports
** Stock down 24% so far this year
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364))
** Shares of Nureca NURE.NS gain as much as 5% to 225.1 rupees, last up 4.3%
** Healthcare and wellness product maker's unit completed registration with the United States Food and Drug Administration (USFDA)
** Medical devices from the unit's plant in Punjab state including beds and stethoscope now listed with USFDA for manufacturing and exports
** Stock down 24% so far this year
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364))
** Healthcare and wellness products maker Nureca NURE.NS rises 9.5% to 333.60 rupees
** Co gets favourable injunction from commercial court against Threpsi Solutions, ARC International and Tech-Connect Retail
** Injunction restrains passing, selling marketing products using NURE's registered trademark "SUPERVOLT" or any deceptively similar mark
** Around 151,005 shares traded, ~4x the 30-day avg
** NURE fell ~34% in 2024
(Reporting by Vijay Malkar)
(([email protected];))
** Healthcare and wellness products maker Nureca NURE.NS rises 9.5% to 333.60 rupees
** Co gets favourable injunction from commercial court against Threpsi Solutions, ARC International and Tech-Connect Retail
** Injunction restrains passing, selling marketing products using NURE's registered trademark "SUPERVOLT" or any deceptively similar mark
** Around 151,005 shares traded, ~4x the 30-day avg
** NURE fell ~34% in 2024
(Reporting by Vijay Malkar)
(([email protected];))
Dec 6 (Reuters) - Nureca Ltd NURE.NS:
NURECA LTD - ACQUIRED SHARES OF YES BANK FOR 9.7 MILLION RUPEES
Source text: ID:nBSE2mqXS6
Further company coverage: NURE.NS
(([email protected];))
Dec 6 (Reuters) - Nureca Ltd NURE.NS:
NURECA LTD - ACQUIRED SHARES OF YES BANK FOR 9.7 MILLION RUPEES
Source text: ID:nBSE2mqXS6
Further company coverage: NURE.NS
(([email protected];))
Dec 4 (Reuters) - Nureca Ltd NURE.NS:
ACQUIRED SHARES OF INDUSIND BANK WORTH 15 MILLION RUPEES
Source text: ID:nBSE5BC2L4
Further company coverage: INBK.NS
(([email protected];;))
Dec 4 (Reuters) - Nureca Ltd NURE.NS:
ACQUIRED SHARES OF INDUSIND BANK WORTH 15 MILLION RUPEES
Source text: ID:nBSE5BC2L4
Further company coverage: INBK.NS
(([email protected];;))
** Shares of healthcare products maker Nureca NURE.NS jump as much as 5.3% to 285.45 rupees
** Co on Saturday entered into an agreement with quick commerce firm Zepto to get NURE's products on Zepto's platform
** Terms of the deal were not disclosed, citing confidentiality
** Stock on track to log biggest one-day gain in around two weeks if trends hold
** NURE last up ~2%, trimming YTD losses to 35%
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of healthcare products maker Nureca NURE.NS jump as much as 5.3% to 285.45 rupees
** Co on Saturday entered into an agreement with quick commerce firm Zepto to get NURE's products on Zepto's platform
** Terms of the deal were not disclosed, citing confidentiality
** Stock on track to log biggest one-day gain in around two weeks if trends hold
** NURE last up ~2%, trimming YTD losses to 35%
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
Sept 17 (Reuters) - Nureca Ltd NURE.NS:
NURECA LTD - ENTERED INTO A DISTRIBUTION AGREEMENT
NURECA - DUE TO ADDITIONAL ORDERS, SALES MAY EXCEED MATERIALITY THRESHOLD IN CURRENT QUARTER
Source text for Eikon: ID:nBSE1ngLKH
Further company coverage: NURE.NS
(([email protected];))
Sept 17 (Reuters) - Nureca Ltd NURE.NS:
NURECA LTD - ENTERED INTO A DISTRIBUTION AGREEMENT
NURECA - DUE TO ADDITIONAL ORDERS, SALES MAY EXCEED MATERIALITY THRESHOLD IN CURRENT QUARTER
Source text for Eikon: ID:nBSE1ngLKH
Further company coverage: NURE.NS
(([email protected];))
Nov 20 (Reuters) - Nureca Ltd NURE.NS:
NURECA LTD - APPROVED APPOINTMENT OF NARESH GUPTA AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nNSE6vZksR
Further company coverage: NURE.NS
(([email protected];))
Nov 20 (Reuters) - Nureca Ltd NURE.NS:
NURECA LTD - APPROVED APPOINTMENT OF NARESH GUPTA AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nNSE6vZksR
Further company coverage: NURE.NS
(([email protected];))
Sept 7 (Reuters) - Nureca Ltd NURE.NS:
NISHANT GARG RESIGNS AS CFO
Source text for Eikon: [ID:]
Further company coverage: NURE.NS
(([email protected];;))
Sept 7 (Reuters) - Nureca Ltd NURE.NS:
NISHANT GARG RESIGNS AS CFO
Source text for Eikon: [ID:]
Further company coverage: NURE.NS
(([email protected];;))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Nureca do?
Nureca Limited is a B2C company offering quality home healthcare and wellness products with innovative designs, sold through online channels and its own website drtrust.in, targeting a wider customer base with a diverse product portfolio.
Who are the competitors of Nureca?
Nureca major competitors are QMS Medi Allied Ser., 3B Blackbio Dx, TTK Healthcare, Poly Medicure, Rajnish Wellness, Max India, Health X Platform. Market Cap of Nureca is ₹316 Crs. While the median market cap of its peers are ₹940 Crs.
Is Nureca financially stable compared to its competitors?
Nureca seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Nureca pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Nureca latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Nureca allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Nureca balance sheet?
Balance sheet of Nureca is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Nureca improving?
Yes, profit is increasing. The profit of Nureca is ₹4.34 Crs for TTM, ₹2.08 Crs for Mar 2026 and ₹0.85 Crs for Mar 2025.
Is the debt of Nureca increasing or decreasing?
Yes, The net debt of Nureca is increasing. Latest net debt of Nureca is -₹82.12 Crs as of Mar-26. This is greater than Mar-25 when it was -₹252.4 Crs.
Is Nureca stock expensive?
Nureca is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Nureca is 73.7, while 3 year average PE is 112. Also latest EV/EBITDA of Nureca is 67.06 while 3yr average is 58.28.
Has the share price of Nureca grown faster than its competition?
Nureca has given lower returns compared to its competitors. Nureca has grown at ~0.82% over the last 3yrs while peers have grown at a median rate of 1.47%
Is the promoter bullish about Nureca?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Nureca is 68.09% and last quarter promoter holding is 68.09%.
Are mutual funds buying/selling Nureca?
There is Insufficient data to gauge this.